CARMA FUND I Completes First Closing of € 47 m to Accelerate the Transfer of Life-Science Research into Practice

On June 21, 2022 Evotec reported that A consortium of strong partners has launched the CARMA FUND I as a new vehicle for the translation of promising early-stage life-science projects: the initiators, Ascenion GmbH, a life-science focused technology transfer company of the LifeScience Foundation and the Goethe-University, Frankfurt am Main with its technology transfer company Innovectis GmbH, together with the European Investment Fund (EIF) and other investors (Press release, Evotec, JUN 21, 2022, View Source [SID1234616113]). The fund will be managed by CARMA FUND Management GmbH, headed by its general partners Christian Leikert and Martin Raditsch.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fund, with a target size of € 60 m and a first closing at € 47 m, will invest in promising start-ups or high-potential academic projects in the life-science field, from Ascenion’s and Innovectis’ partner institutions. However, outstanding innovations or spin-offs from other German or European research organizations will also be considered as investment targets. Projects will be selected for their scientific excellence and potential to deliver outstanding societal or patient benefits and financial returns. CARMA is open to the full breadth of life-science and medical innovation, including new therapeutic and diagnostic approaches, platform technologies, medical devices and digital health. Along with funding, the projects will benefit from the partners’ network of distinguished top-level industry representatives and experts.

For further information, please follow this link to the press releases from Goethe-University, Frankfurt am Main and Ascenion, respectively.